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ABSTRACT 
Cancer is a disease that is causing an increase in mortality all over the world. Cancer treatment is expensive and has a variety of side effects. Natural 
compound treatment is an attempt to reduce the side effects of cancer therapy. Mangiferin is a natural compound with anticancer and 
immunomodulatory activity. The immunomodulatory activity of mangiferin from mango (Mangifera indica L.) in cancer was discussed in this article. 
The literature used in this review was obtained from several databases, including the Cochrane Library, Google Scholar, PubMed, ProQuest, 
ScienceDirect, and the Wiley Online Library, for articles published over the last ten years.  
Mangiferin influenced anticancer activity by inhibiting NF-κB, affects the regulation of β-catenin, EMT, MMP2, MMP9, LDH, NO, ROS, and inhibits 
classical macrophages activation. 
Mangiferin has an immunomodulatory effect that can be developed as a candidate drug for anticancer therapy. 
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INTRODUCTION 
Cancer is a disease that has a high prevalence worldwide. Cancer 
treatment requires high costs and various side effects that can affect 
the quality of life [1, 2]. Cancer ranks first cause of death in every 
country. In 2019, cancer was the leading cause of death under the 
age of 70. Based on the WHO report, in 2020, there be 19.3 million 
cancer cases and almost 10 million cancer deaths [3]. 
Currently, cancer treatment is experiencing rapid development with 
the hope of decreasing cancer mortality. One of the cancer 
treatments is immunotherapy [4]. Food and Drug Administration 
(FDA) approved immunotherapy drugs for cancer, namely 
vemurafenib, and ipilimumab. Vemurafenib works by inhibiting the 
b-rapidly accelerated fibrosarcoma (BRAF) protein, and the 
ipilimumab activates the immune system [5]. Immunomodulators 
are natural and adaptive compounds that can modulate the immune 
response. Immunomodulators are classified as adjuvants, 
suppressants and stimulants [6]. Stimulant-type immunomodulators 
in cancer restore the damaged immune system by activating the 
body's defense mechanisms [7].  
In cancer, various immune responses are activated to avoid damage 
to the immune system [8]. Cancer cells will detect immune cells likes 
T cells and macrophages, resulting in increased levels of 
proinflammatory cytokines that stimulate NF-κB activation and 
encourage proliferation and metastasis [9]. T cells play an essential 
role in immune and antitumor responses, while B cells help in 
producing antibodies [10]. T cell receptor (TCR) and CD3 gene 
increase TCR expression leading to faster tumor clearance [11, 12].  
Many drugs derived from plants are sensitive and effective against 
tumor development, prolong patients' survival time, and prevent 
side effects of chemotherapy [13–15]. One of them is mango 
(Mangifera indica L.) which belongs to the Anacardiaceae family, 
widely used as food, cosmetics, and medicine (16]. It is found in 
tropical and subtropical regions and is one of the most popular fruits 
with low calories and high fiber [17, 18]. Mango contains polyphenol 
compounds (40-60%), a potentially therapeutic phytochemical 
compound (19]. Various studies had shown that polyphenols have 
anti-inflammatory and immunomodulatory [20, 21]. Polyphenol can 
also protect DNA from gamma-ray damage, which suggests that 
polyphenols act as radioprotection [22]. In mango, the most 
well-known compound is mangiferin [23]. 
 
 
Fig. 1: Chemical structure of mangiferin 
 
Mangiferin compounds (1,3,6,7-tetrahydroxyflavonoid-C2-β-D- 
glucoside) (fig. 1) are the compounds derived from the leaves and 
skin of mango [24, 25]. Several studies have shown that the natural 
compound mangiferin has an anticancer activity where this 
compound can increase the sensitivity of cancer cells to anticancer 
drugs [26, 27]. Mangiferin also showed anti-inflammatory, 
antidiabetic, antioxidants, hypolipidemic, antiviral, 
immunomodulators, analgesics, and hepatoprotective activity 
[28-30]. Studies show that mangiferin has an immunomodulatory on 
T-cells and B-cells [31]. So far, there is no clinical evidence of side 
effects of mangiferin. This compound could be a candidate in drug 
development [32]. This article aims to summarize the 
immunomodulatory activity of mangiferin compounds in cancer. 
Method of collecting data 
A comprehensive search was carried out by collecting publications 
from several databases, i.e., Cochrane Library, Google Scholar, 
PubMed, ProQuest, ScienceDirect, and the Wiley Online Library. The 
keywords used were "(cancer) AND (mangiferin) AND 
(immunomodulator)." The literature used is an article published in 
the last ten years. Fig. 2 showed the flow chart of this systematic 
review.
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Fig. 2: Flow chart systematic review 
 
Selection of articles 
There are 2060 articles obtained from search results using 
keywords for articles published in the last ten years (0 articles from 
the Cochrane Library, 1416 articles from Google Scholar, two 
articles from PubMed, 555 articles from ProQuest, 32 articles from 
ScienceDirect, and 55 articles from the Wiley Online Library). After 
screening the title, abstract, and other variables, 285 articles met the 
inclusion criteria. After screening the full text, six articles meet the 
requirements, and it used in this review.  
Mangiferin as NF-κB inhibitors 
Natural compounds exhibit cytotoxic potential against cancer cells 
by causing apoptosis and suppressing Nuclear factor-kappa B 
(NF-κB) [33]. NF-κB is a transcription factor in the immune system 
with an anti-apoptotic effect, which works to increase the resistance 
of cancer cells [34]. Activation of NF-κB will increase the formation 
of TNF-α and IL-1β [35]. NF-κB is commonly used to promote tumor 
formation and regulate angiogenesis [36].  
A study by du Plessis-Stoman et al. shows mangiferin act as NF-κB 
inhibitor and cause a reduction in NF-κB activation in cancer cells. 
Furthermore, the combination of oxaliplatin-mangiferin 10 µg mol/l 
increases IC50 in resistance cancer cells by modulating NF-κB. 
Mangiferin increased the percentage of dead cells with leakage of 
the cell membrane, with less necrosis occurred. These results 
suggest that mangiferin emphasizes cell death by apoptosis rather 
than necrosis [37,38] with oxaliplatin-mangiferin 10 µg mol/l [38]. 
Polyphenolic compounds such as mangiferin can affect signaling 
genes in the NF-κB pathway [39]. It inhibits not only NF-κB signaling 
but also inhibits phosphorylation of the mitogen-activated protein 
kinase signaling molecule (MAPK), including extracellular 
signal-regulated kinase (ERK1/2), jun-n terminal kinase (JNK), and 
p38 [40].  
Mangiferin influences the regulation of β-catenin, EMT, MMP2, 
and MMP9 
Administration of mangiferin 300 µM in ovarian clear cell 
endocervix (ES-2) produces an anti-MMP effect. It can inhibit the 
process of invasion, metastasis, angiogenesis in tumor cells. 
Mangiferin has also inhibited the β-catenin pathway, which plays an 
important role in anticancer activity [41]. β-catenin is a 
dual-function protein involved in regulating and coordinating cell 
adhesion and gene transcription, which plays an important role in 
the survival and regeneration of cells [42]. β-catenin modulates the 
proliferation of epithelial-mesenchymal transition cells (EMT) and 
matrix metalloproteinases (MMP). EMT is a process characterized 
by loss of adhesion with inhibition of closely related cell β-catenin, 
thereby leading to metastasis [43]. Meanwhile, MMP has the 
potential as a therapeutic target for cancer [44]. In the process of 
metastasis, MMP2 and MMP9 result in extracellular cleavage of 
matrix proteins in cancer cells by contributing to the epithelial to 
mesenchymal transition, which is the first step for cancer cells to 
become abnormal [45].  
Mangiferin induces cytotoxicity by regulating LDH, NO, and ROS 
The administration of 70 µM mangiferin toxic on 
rhabdomyosarcoma (RD) cells by using the MTT method. The 
mangiferin-induced cell death in RD cells is determined by lactate 
dehydrogenase and nitric oxide, generating reactive oxygen species 
in mitochondrial membranes [46]. Lactate dehydrogenase (LDH) is 
an enzyme produced by the cytosol. The increase in this enzyme 
occurred when the cell membrane was damaged by cytotoxicity. 
Nitric oxide (NO) plays a role in cellular signaling, and in high 
concentrations, NO has a cytotoxic effect [47]. NO can regulate many 
physiological processes that cause damage to DNA, proteins, and 
lipid molecules, leading to apoptosis [48]. One of the NO targets for 
maintaining thiol status and modulation of cell proliferation is 
glutathione (GSH) [49]. Research shows that NO induce GSH to make 
cells sensitive to cytotoxicity [50]. GSH forms oxidation products due 
to mangiferin, which leads to reactive oxygen species (ROS) 
generation. ROS plays a vital role in inducing cancer cell apoptosis 
[51]. Administration of 0.5 µM mangiferin to Mia-PaCa2 cells 
showed a significant increase in ROS levels so that it could induce 
apoptosis in cancer cells [52]. 
Mangiferin inhibits the activation of classic macrophages 
Polarized macrophages release a large number of proinflammatory 
cytokines, including tumor necrosis factor-alpha (TNF-α), 
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interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and interleukin-8 
(IL-8). Proinflammatory cytokines play an important role in the 
immune system response. Excessive production of cytokines will 
cause tissue and cell damage to induce cancer cell death through the 
proliferation process. Studies show that the levels of TNF-α, IL-1β, 
IL-6, and IL-8 in THP-1 cells can be reduced by stimulating 
lipopolysaccharides/interferon-gamma (LPS/IFN-γ) [53]. 
Administration of mangiferin 100 and 200 µmol/l to human THP-1 
cells can significantly increase TNF-α, IL-1β, IL-6, and IL-8 [54]. 
Mangiferin also plays a role in reducing interferon regulatory factor 
5 (IRF5), an important factor in regulating classical macrophage 
activation [55]. Classical macrophage activation is required for 
normal protection in the immune response. Thus, mangiferin 
produces beneficial disease-fighting effects that have potential in 
cancer therapy [56]. 
 
 
Fig. 3: Mangiferin mechanism to the immune system in cancer 
 
CONCLUSION 
Mangiferin in mango (Mangifera indica L.) potential as candidates 
drug in cancer. The effect of mangiferin on the immune system can 
treat cancer through various mechanisms. It works to inhibit NF-κB, 
anti-MMP, cytotoxic induction through LDH, NO, ROS regulation and 
inhibits the activation of classic macrophages. It can be developed in 
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